Achilles Therapeutics Plc Stock Short Ratio
| ACHL Stock | USD 1.05 0.02 1.94% |
Achilles Therapeutics PLC fundamentals help investors to digest information that contributes to Achilles Therapeutics' financial success or failures. It also enables traders to predict the movement of Achilles Stock. The fundamental analysis module provides a way to measure Achilles Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Achilles Therapeutics stock.
Achilles | Short Ratio |
Achilles Therapeutics PLC Company Short Ratio Analysis
Achilles Therapeutics' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Achilles Therapeutics Short Ratio | 0.12 X |
Most of Achilles Therapeutics' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Achilles Therapeutics PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Achilles Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Achilles Therapeutics is extremely important. It helps to project a fair market value of Achilles Stock properly, considering its historical fundamentals such as Short Ratio. Since Achilles Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Achilles Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Achilles Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, Achilles Therapeutics PLC has a Short Ratio of 0.12 times. This is 96.92% lower than that of the Biotechnology sector and 98.38% lower than that of the Health Care industry. The short ratio for all United States stocks is 97.0% higher than that of the company.
Achilles Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Achilles Therapeutics' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Achilles Therapeutics could also be used in its relative valuation, which is a method of valuing Achilles Therapeutics by comparing valuation metrics of similar companies.Achilles Therapeutics is currently under evaluation in short ratio category among its peers.
Achilles Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Achilles Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Achilles Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Achilles Therapeutics' value.| Shares | Citadel Advisors Llc | 2024-06-30 | 61.4 K | Xtx Topco Ltd | 2024-06-30 | 51.7 K | Two Sigma Advisers, Llc | 2024-06-30 | 23.5 K | Virtu Financial Llc | 2024-06-30 | 22.8 K | Geode Capital Management, Llc | 2024-06-30 | 21.6 K | Two Sigma Investments Llc | 2024-06-30 | 21.5 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 17.9 K | Baader Bank Inc | 2024-06-30 | 12.4 K | Hrt Financial Llc | 2024-06-30 | 10.9 K | Syncona Portfolio Ltd. | 2024-06-30 | 11.1 M | Bml Capital Management Llc | 2024-09-30 | 4.1 M |
Achilles Fundamentals
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | (45.81 M) | ||||
| Shares Outstanding | 41.09 M | ||||
| Shares Owned By Insiders | 6.51 % | ||||
| Shares Owned By Institutions | 62.47 % | ||||
| Number Of Shares Shorted | 212.55 K | ||||
| Price To Earning | 0.49 X | ||||
| Price To Book | 0.37 X | ||||
| EBITDA | (70.44 M) | ||||
| Net Income | (69.94 M) | ||||
| Cash And Equivalents | 201.6 M | ||||
| Cash Per Share | 4.94 X | ||||
| Total Debt | 4.62 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 11.45 X | ||||
| Book Value Per Share | 2.81 X | ||||
| Cash Flow From Operations | (48.64 M) | ||||
| Short Ratio | 0.12 X | ||||
| Earnings Per Share | (1.59) X | ||||
| Price To Earnings To Growth | (0.31) X | ||||
| Target Price | 2.83 | ||||
| Number Of Employees | 204 | ||||
| Beta | 1.34 | ||||
| Market Capitalization | 44.84 M | ||||
| Total Asset | 161.46 M | ||||
| Retained Earnings | (259.95 M) | ||||
| Working Capital | 128.64 M | ||||
| Net Asset | 161.46 M |
About Achilles Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Achilles Therapeutics PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Achilles Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Achilles Therapeutics PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Achilles Therapeutics Piotroski F Score and Achilles Therapeutics Altman Z Score analysis. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.59) | Return On Assets (0.27) | Return On Equity (0.44) |
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.